GlassScriptPhysician profile
Michele Adams
NPI 1588184808
$1,700.31
in general payments reported to CMS, 2019-2025
19 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $750 · 2024: $517 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.10 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $436.66 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $239.97 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.61 | 2023-2025 | |
| Lilly USA, LLC | $152.87 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Organon LLC | $108.15 | 2023 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $106.55 | 2023-2024 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Exeltis, USA INC. | $99.28 | 2023 | Slynd |
| Exact Sciences Corporation | $84.42 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $44.82 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $41.35 | 2023-2024 | Gardasil 9, Gardasil |
| Agile Therapeutics, INC. | $40.29 | 2023-2024 | Twirla |
| Hologic Sales and Service, LLC | $37.87 | 2024-2025 | Aptima |
| Therapeuticsmd, INC. | $36.94 | 2022 | |
| Axsome Therapeutics, INC. | $30.36 | 2025 | Symbravo |
| Abbvie INC. | $19.40 | 2023 | Lo Loestrin Fe, Orilissa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.09 | 2024 | Wegovy |
| Daiichi Sankyo INC. | $15.63 | 2022 | |
| Sumitomo Pharma America, INC. | $15.52 | 2023 | Myfembree |
| Pfizer INC. | $13.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.